SANGAMO THERAPEUTICS, INC (SGMO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, SANGAMO THERAPEUTICS, INC reported revenue of $39.55M, down 31.6% from the prior year. The company ran a net loss, with a net margin of -310.8%. It held $59.74M in total assets against $74.01M in total liabilities.
Key ratios (FY2025)
-306.5%
Operating margin
-310.8%
Net margin
-31.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.55M | $57.80M | $176.23M | $111.30M | $110.70M | $118.19M | $102.43M | $84.45M | $36.57M | $19.39M |
| Operating Income | -$121.24M | -$103.97M | -$274.00M | -$201.28M | -$183.34M | -$129.55M | -$105.18M | -$77.15M | -$56.36M | -$72.56M |
| Net Income | -$122.93M | -$97.94M | -$257.83M | -$192.28M | -$178.29M | -$121.00M | -$95.19M | -$68.33M | -$54.57M | -$71.66M |
| EPS (Diluted) | $-0.44 | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.85 | — | — | — |
| Total Assets | $59.74M | $101.64M | $165.32M | $562.51M | $721.92M | $938.55M | $637.52M | $590.39M | $286.74M | $157.89M |
| Total Liabilities | $74.01M | $78.86M | $82.43M | $267.55M | $346.58M | $441.18M | $204.78M | $223.14M | $98.84M | $21.70M |
| Shareholders' Equity | -$14.27M | $22.77M | $82.89M | $294.96M | $375.34M | $498.23M | $432.55M | $366.52M | $187.90M | $136.19M |
| Cash & Equivalents | $20.95M | $41.92M | $45.20M | $100.44M | $178.87M | $131.33M | $80.43M | $140.42M | $49.83M | $22.06M |
| Operating Cash Flow | -$97.21M | -$67.14M | -$224.84M | -$223.63M | -$233.25M | $169.88M | -$144.40M | $36.55M | $11.18M | -$65.88M |
| Capital Expenditures | $102.0K | $267.0K | $21.16M | $20.17M | $23.28M | $14.71M | $20.68M | $43.06M | $3.75M | $732.0K |
| Shares Outstanding | 350.69M | 212.84M | 178.13M | 166.79M | 145.92M | 142.06M | 115.97M | 102.19M | 85.60M | 70.87M |